Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market

USD 3,950.00

* Required Fields

USD 3,950.00


Be the first to review this product

The dermatology space has been transformed with the introduction of biologic therapy for psoriasis, with several additional novel drug classes on the verge of market introduction. This research service provides a comprehensive overview and analysis of marketed and investigational products for the treatment of psoriasis. Information on market background and a global overview and analysis of drug development, detailed product and pipeline analysis by disease severity, drug class and stage of development, and detailed product dashboards for key marketed and late-stage products are also included in the study.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued)Methodology and ScopeMethodology and ScopeIntroductionIntroductionMarket BackgroundDisease ClassificationEpidemiologyEpidemiology (continued)Efficacy Assessment ToolsSegmentationSegmentation (continued)Segmentation (continued)Psoriasis Therapeutics MarketCompetitive Landscape—Mild-to-moderate PS, Products in DevelopmentCompetitive Landscape—Moderate-to-severe PS, Marketed Products and Products in DevelopmentCompetitive Landscape—Pivotal Phase 3 TrialsCompetitive Landscape—Pivotal Phase 3 Trials (continued)Timeline of Key EventsComparative Efficacy of Select Marketed and Investigational DrugsComparative Efficacy DiscussionMarketed Products AnalysisMarketed Products Analysis (continued)Marketed Products Analysis (continued)Marketed Products Analysis (continued)Marketed Products Analysis (continued)Pipeline AnalysisPipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Pipeline Analysis (continued)Product Dashboard—Enbrel (etanercept)Product Dashboard—Remicade (infliximab)Product Dashboard—Humira (adalimumab)Product Dashboard—Stelara (ustekimunab)Product Dashboard—Secukinumab (AIN457)Product Dashboard—Izekizumab (LY2439821)Product Dashboard—Brodalumab (AMG 827)Product Dashboard—ApremilastProduct Dashboard—Xeljanz (tofacitinib)Product Dashboard—Tildrakizumab (MK-3222)Conclusions and RecommendationsConclusions and Recommendations Conclusions and Recommendations (continued)New Market OpportunitiesCompanies to WatchLegal DisclaimerAppendixComparative Efficacy of Select Marketed and Investigational DrugsThe Frost & Sullivan StoryWho is Frost & SullivanWhat Makes Us UniqueTEAM MethodologyOur Global Footprint 40+ Offices

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.